Iambic Therapeutics
AI-driven drug discovery company using deep learning to accelerate the development of novel small molecule therapeutics, with programs in oncology and immunology.
Notes
Iambic Therapeutics is an AI-driven drug discovery company using proprietary deep learning technology to accelerate the development of novel small molecule medicines. The company's platform combines AI-powered molecule generation and optimization with rapid experimental validation.
Founded in 2019, Iambic emerged from research on using machine learning to improve drug discovery efficiency. The company claims its AI platform can significantly reduce the time from target identification to clinical candidate compared to traditional drug discovery timelines.
Iambic has developed internal pipeline programs in oncology and immunology, while also pursuing partnerships with pharmaceutical companies interested in applying AI to their drug discovery efforts.
Team
- Tom Miller - CEO
- LinkedIn: linkedin.com/in/tommiller
- Team combines expertise in AI/ML, computational chemistry, and drug development
Additional Research Findings
- Founded in 2019 in San Diego, California
- AI-first drug discovery platform
- Deep learning for molecule design and optimization
- Internal programs in oncology and immunology
- Partnerships with pharmaceutical companies
- Raised significant Series A and B funding
- Backed by top tech and life science investors
- Claims 10x faster drug discovery timelines
- Focus on small molecule therapeutics
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |